The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
TREMFYA Janssen-Cilag Pty Ltd
Product name
TREMFYA
Sponsor
Accepted date
Jan-2025
Active ingredients
guselkumab
Proposed indication
TREMFYA is used to treat children aged 6 years and older with moderate to severe plaque psoriasis who are eligible for systemic (whole-body) therapy or phototherapy (ultraviolet light therapy).
Application type
C (new indication)
Publication date
Jan-2025